



Short Communication

Very rare condition of multiple Gaucheroma: A case report and review of the literature[☆]

Szu-Yin Tseng^{a,h}, Dau-Ming Niu^{a,h}, Tzu-Hung Chu^{a,h}, Yi-Chen Yeh^c, Man-Hsu Huang^c, Tsui-Feng Yang^g, Hsuan-Chieh Liao^{d,e}, Chuan-Chi Chiang^d, Hui-Chen Ho^f, Wen-Jue Soong^a, Chia-Feng Yang^{a,b,*}

^a Department of Pediatrics, Taipei Veterans General Hospital, Taiwan, ROC

^b Institute of Environmental and Occupational Health Sciences, National Yang-Ming University, Taiwan, ROC

^c Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taiwan, ROC

^d The Chinese Foundation of Health Neonatal Screening Center, Taiwan, ROC

^e Institute of Clinical Medicine, National Yang-Ming University, Taiwan, ROC

^f Taipei Institute of Pathology, Taiwan, ROC

^g Physical Medicine and Rehabilitation Department, Taipei Veterans General Hospital, Taiwan, ROC

^h Department of Pediatrics, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

ARTICLE INFO

Keywords:

Gaucher disease
Gaucheroma
Enzyme replacement therapy(ERT)
Lysosomal storage disease(LSD)
Liver mass

ABSTRACT

Background: This study presented a 3 years old boy with Gaucher disease (GD) who was treated with enzyme replacement therapy(ERT) for 19 months and developed multiple Gaucheroma. The literature was reviewed.

Methods: The medical chart and literature were reviewed. A boy presented at the age of 15 months with anemia, thrombocytopenia, and hepatosplenomegaly. Enzyme assay and gene mutations confirmed GD. ERT was administered. When the boy was 3 years old, multiple masses were discovered from abdominal MRI and biopsy revealed Gaucheroma. We reviewed 20 GD patients with Gaucheroma and Gaucher cell infiltrated lymphadenopathies.

Conclusion: Gaucheroma is a rare condition in regularly treated GD patients. This patient showed poor response to doubled ERT doses. The imaging studies are necessary for Gaucher patients to detect Gaucheroma and determine their malignancy. Regular checkups are recommended in all GD patients even with ERT treatment, due to the possibility of having a deteriorating change, like Gaucheroma.

1. Introduction

Gaucher disease (GD) is the most common lysosomal storage disease (LSD) worldwide [1]. GD is caused by mutation of the GBA gene [2,3], which decreased activity of β -glucocerebrosidase and result in the accumulation of glucosylceramide in macrophages [2]. This leads to the transformation of macrophages into Gaucher cells. It is believed that the infiltration of Gaucher cells into organs contributes to the presence of clinical symptoms. There are three phenotypic variants in GD, non-neuropathic GD (type 1), acute and chronic neuropathic GD (type 2 and 3 GD, respectively).

The treatments for GD are intravenous enzyme replacement therapy (ERT), oral substrate reduction therapy (SRT) and pharmacological

chaperone therapy. The recommended ERT dose is 60–120 IU/kg every other week. Anemia may be corrected during the first 6 months of treatment [4]. The platelet response varies depending on the degree of splenomegaly and the initial platelet count. In moderate cases, organomegaly will improve after treatment for 12 to 24 months. The treatment response to skeletal pathology and pulmonary diseases are less significant [4].

Despite the current treatment options, patients with GD remain eligible to develop complications, including multiple myeloma and malignancies [2]. If a focal lesion develops in a patient with GD it should be carefully considered because of the increased risk of malignancy. However, Gaucheromas, which are pseudotumors formed by the accumulation of Gaucher cells have also been reported. The exact

Abbreviations: GD, Gaucher disease; ERT, Enzyme replacement therapy; LSD, Lysosomal storage disease; SRT, substrate reduction therapy; DBS, dried blood test

[☆] Supported by the Taipei Veterans General Hospital (V108B-005).

* Corresponding author at: Department of Pediatrics, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Rd., Beitou District, Taipei City 11217, Taiwan ROC

E-mail address: pum_chia@yahoo.com.tw (C.-F. Yang).

<https://doi.org/10.1016/j.ymgmr.2019.100489>

Received 18 April 2019; Received in revised form 23 June 2019

Available online 12 July 2019

2214-4269/ © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

pathophysiology of Gaucheromas remains unknown. This study presents the youngest patient who was treated with ERT and developed Gaucheroma after receiving ERT for 19 months. We also did the review of the all reported Gaucheroma patients.

2. Material and methods

The medical chart and literature were reviewed. A 15 months old boy was brought for a vaccination. The physical examination found he had hepatosplenomegaly. His mother reported that he had progressive abdominal distension for 2 months prior to his hospital visit. The boy's body height was below the 3rd percentile, and his body weight was within the 3rd to 15th percentile for his age. The developmental milestone showed he could not stand and still needed help to walk. He was born at full term and his past medical and family history were unremarkable. He had anemia (Hgb, 8.8 g/dL) and thrombocytopenia (Plt, 85,000/ μ L) at presentation. The boy was transferred to the tertiary center for further examination. A bone marrow aspiration was conducted, and the result revealed "wrinkled-paper cytoplasm" in his CD68+ histiocytes. A leukocyte enzyme assay reported decreased β -glucocerebrosidase activity (1.5 μ M/L/h; reference, > 7.5 μ M/L/h). Genetic study was performed and confirmed a homozygous mutation on the GBA gene at c.1448 T > C, p.L483P (L444P). The Bayley Scales of Infant Development showed a result compatible with his age, except for a mild delay in gross motor skills.

Following his diagnosis, the patient received ERT (imiglucerase 60 IU/kg) every two weeks. After 6 months of ERT treatment, the patient was able to meet therapeutic goals for GD defined by Pastores et al. [5]. The Hgb was increased to 11.6 g/L and his platelet count reached 118,000/ mm^3 . His dried blood test (DBS) CCL18 level had dropped to 136.25 ng/mL. The liver volume was 3.9 times higher than normal before and had decreased to 2.3 times higher than normal. The splenomegaly had also dropped from 24.3 times larger than normal to 8 times larger than normal.

Unfortunately, after ERT for 19 months, a regular abdominal MRI exam revealed a 3.5 \times 2.3 cm hypointense under T1 lobulated mass, at S5 and S6 in the liver. (Fig. 1) Clustered enlarged lymph nodes at the mesenteric and inguinal regions were also discovered. (Fig. 2).

A pediatric hematologist was consulted as hematological malignancy could not be ruled out. Therefore, the patient underwent an open biopsy and repeat bone marrow aspiration due to the suspicious malignancy conditions. Pathology of the liver mass and lymph nodes both revealed cell cytoplasm with "wrinkle-paper like" characteristics, which identified the Gaucheroma (Fig. 3A and B). Bone marrow studies were also confirmed as negative for immature cells and revealed a decreased number of Gaucher cells compared with the original exam at the time of diagnosis (Fig. 4A and B).




Fig. 1. T1 weighted MRI, noted a hypointense, with intersepted appearance, rim enhancement, and restricted diffusion mass (arrow), which measured 3.5 \times 2.3 cm in size.



Fig. 2. Multiple clustered enlarged lymph nodes at mesentery (arrow head). Several small lymph nodes at bilateral inguinal regions.





Fig. 3. (A) Biopsy of Gaucheroma under high-power field. The image shows the accumulation of glucocerebroside in Kupffer cells/macrophages, which formed Gaucher cells in the liver sinusoid and presented with a typical "wrinkle-paper like" appearance under the microscope. (B) The reactivity against CD163 showed a positive reaction.




Fig. 4. Bone marrow biopsy under low-power field (A) before and (B) after the patient received ERT.

A remarkable decreased in the number of infiltrated Gaucher cells was noted after 19 months of ERT treatment. Because of the Gaucheroma, the patient started to receive double dose of ERT (imiglucerase 120 IU/kg) every two weeks. Unfortunately, the sizes of all the Gaucheromas didn't change after one year of ERT titration.

We searched and reviewed the literature related to the Gaucheroma and Gaucher cell infiltrated lymphadenopathies. We found 20 reported patients (Table 1). The presence of Gaucheroma after the commencement of ERT ranges from 1.3 to 17 years. The patient in the current study developed Gaucheroma after 19 months of treatment. This is thought to be the youngest patient to develop Gaucheroma. In patients who use a standard dose of 60 IU/kg every other week, Ivanova et al. reported that three patients developed extraosseous Gaucheroma [5]. There were two GD patients with a homozygous L483P(L444P) mutation. Another GD1 patient had a N370S/L444P. Poll et al. reported that a Gaucheroma presented in the liver, which mimicked focal nodular hyperplasia under MRI [6]. Korula et al. reported that a GD1 patient with homozygous c.1193G > A developed a liver Gaucheroma [7]. 14 patients developed Gaucher cell infiltrated lymphadenopathies in mesenteric, mediastinal, cervical or axillary were reported by 5 studies [8–12].

3. Discussion

The present patient is the youngest reported as having Gaucheroma. Due to the involvement of multiple systems in GD, patients' treatment and care require consultation between different specialists to achieve optimal outcomes [4,13]. We should raise the awareness of GD to avoid invasive procedure before the diagnosis.

Gaucheroma, a focal lesion, either multiple or solitary, composed of

accumulated Gaucher cells has been well documented before the use of ERT [14,15]. The reported prevalence of splenic and hepatic lesions has ranged from 19 to 33% [16–18] and 6 to 20% respectively [18,19] for all ages. Since the commencement of ERT to treat Gaucher patients, the natural course of the disease has changed. A “pseudotumor” made up of a cluster of Gaucher cells (termed a Gaucheroma), is a rare condition which has been found in the liver, spleen, and bone [5–7] in patients who received ERT [6]. Kourla et al. proposed a combination of SRT or a higher dose of ERT as a treatment for the Gaucheroma. However, the lesion mass showed interval reduction in size if a standard ERT dose was maintained [7]. In our study, there is no interval change of Gaucheroma after doubled the dose of ERT for one year. The responses of ERT vary in different organs and even in patients who share the same mutation [20]. These poor ERT responses point out the more complex pathophysiology in GD and the influences of varies penetrations ability in organs, possible by the differentiated expression of the mannose receptors on the tissue macrophages which not only affect the uptake rate but also proper trafficking to the lysosome once the exogenous ERT is internalized in the cell [5,21,22].

The image presentation of Gaucheroma is very diverse and might be indistinguishable from malignancies, such as hepatocellular carcinoma or lymphoma [23]. This might cause delay recognition of the Gaucheroma. In our study, we performed the biopsy of liver mass and reported the accumulation of glucocerebroside in Kupffer cells/macrophages and the positive reactivity against CD163 to prove this Gaucheroma lesion. Gaucheroma developed in the present patient despite him showing disease improvement. The condition also indicated the insufficiency of current treatment goals and biomarkers to evaluate GD patients.

GD is believed to alter the regulation of the immune system and inflammation, which may result in chronic inflammation. Gaucher cells share some features with the M2 phenotype, including CD163 and CD68. However they do not express cytokines but they do express VEGF [5]. These findings are thought to be related to increased malignant risks in patients with GD and may contribute to the formation of Gaucheroma by attracts migration of these Gaucher cells [2,5,22]. Regenboog et al. proposed an algorithm for management the hepatic lesions in GD patients [23]. Due to the risk of malignancy in GD patients, the condition remains a great burden for physicians when deciding on treatment options. In Gaucher patients, regular imaging follow-up, including chest and abdominal MRI for possible interval changes may be required, even for the patients who have received ERT. The pathological proof was acquired in suspected patients of malignancy. The exact mechanism of Gaucheroma was unknown. It might relate to different cell characteristics or differential expression of mannose receptors from other Gaucher cells. Further research was requested for improving the long-term outcome of Gaucher disease.

4. Conclusion

To the best of our knowledge, the current study presents the youngest reported patient of Gaucheroma, who have already received standing and regular ERT. Previous literature has reported that the onset of Gaucheroma ranges from 1.3 to 17 years after the commencement of ERT. All patients in the studies received the standard dose of 60 IU/kg every two weeks. The Gaucheroma failed to show improvement after titration the ERT doses. Regular imaging studies are recommended in GD patients, due to the possibility of having a deteriorating change, like Gaucheroma and the higher risk of malignancy in patients.

Disclosure statement

The authors declare no conflicts of interest. The preliminary report has been published as an abstract. (Annals of Translational Medicine, Vol 5, Suppl 2 September 2017, doi: 10.21037/atm.2017.s029).

Table 1
List of the reported patients of Gaucheroma.

Study	Type	Duration of treatment before Gaucheroma	Age of start treatment	Dose (IU/kg/QOW)	Genotype	Primary site
Tseng 2018 ^a	3	1.5y	15mo	60	L444P/L444P	Liver Mesenteric LN
Lim 2002 ^b	3	2y	13mo	–	–	Mesenteric LN
Fowler 2006 ¹¹	–	1.8y	2.2y	–	–	Mesenteric LN
	–	7y	1y	–	L444P/L444P	Mesenteric LN
Burrow 2007 ⁹	3	1.3y	1.7y	60	D409H L444P A456P/A456P	Mesenteric and mediastinal LN
Poll 2009 ⁶	–	–	–	–	–	Liver
Yağci 2009 ¹⁰	1/3 ^b	3.4y	18mo	60	L444P/?	Mesenteric LN
Lee 2012 ¹²	3	3.6y	1y	40	L444P/L444P	Mesenteric LN
Abdelwahab 2015 [24]	1	2y	4y	60	R359Q/R359Q	Mesenteric and mediastinal LN
				120 ^c < 60 ^d		
	1	2.5y	1y	60	–	Mesenteric and mediastinal LN
				< 60 ^d		
	1	3y	4.5y	60	–	Mesenteric LN
				< 60 ^d		
	3	3.5y	18mo	60	L444P/L444P	Mesenteric and mediastinal LN
				> 60 ^c < 60 ^d		
	3	1.5y	2y	60	L444P/L444P	Cervical and axillary LN
				< 60 ^d		
	3	7.5y	1.5y	60	L444P/L444P	Mesenteric LN
	3	3y	2y	60	L444P/L444P	Mesenteric and mediastinal LN
				30 ^d 60		
	3	4y	14mo	120	L444P/L444P	Mesenteric, mediastinal, cervical, axillary LN
				< 60 ^d 60		
Korula 2016 ⁷	1	3.5y	15mo	60	Homozygous c.1193G > A	Liver
Ivanovae 2016 ⁵	3	8.5y	18mo	60	L444P/L444P	Osseous and Extrasosseous
	3	17 y	12mo	60	L444P/L444P	Extrasosseous
	1	5 y	65 yr	60	N370S/L444P	Extrasosseous

LN: lymph nodes.

Adapted from Lee, B. H. et al. Progressive mesenteric lymphadenopathy with protein-losing enteropathy; a devastating complication in Gaucher disease. *Mol Genet Metab* 105, 522–524, (2012).

^a Our patient.

^b Unable to differentiate phenotype due to young age.

^c Dose increased after diagnosed of Gaucheroma.

^d Dose decreased during Imiglucerase shortage.

Declaration of Competing Interest

The authors declare no conflicts of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

This work was supported by grants from the Division of Pediatric Surgery, Taipei Veterans General Hospital and Department of Radiology, Taipei Veterans General Hospital.

References

- [1] P.J. Meikle, J.J. Hopwood, A.E. Clague, W.F. Carey, Prevalence of lysosomal storage disorders, *Jama* 281 (1999) 249–254.
- [2] J. Stirmemann, et al., A review of Gaucher disease pathophysiology, clinical presentation and treatments, *Int. J. Mol. Sci.* 18 (2017), <https://doi.org/10.3390/ijms18020441>.
- [3] B.E. Rosenbloom, N.J. Weinreb, Gaucher disease: a comprehensive review, *Crit. Rev. Oncol.* 18 (2013) 163–175.
- [4] G.M. Pastores, et al., Therapeutic goals in the treatment of Gaucher disease, *Semin. Hematol.* 41 (2004) 4–14.
- [5] M. Ivanova, et al., Gaucheromas: when macrophages promote tumor formation and dissemination, *Blood Cells Mol. Dis.* (2016), <https://doi.org/10.1016/j.bcmd.2016.10.018>.
- [6] L.W. Poll, S. vom Dahl, Hepatic Gaucheroma mimicking focal nodular hyperplasia, *Hepatology* 50 (2009) 985–986, <https://doi.org/10.1002/hep.23183>.
- [7] S. Ikorula, P. Owens, A. Charlton, K. Bhattacharya, Rare case of hepatic Gaucheroma in a child on enzyme replacement therapy, *JIMD Rep.* 32 (2017) 101–104, https://doi.org/10.1007/8904_2016_562.
- [8] A.K. Lim, A. Vellodi, K. McHugh, Mesenteric mass in a young girl—an unusual site for Gaucher's disease, *Pediatr. Radiol.* 32 (2002) 674–676, <https://doi.org/10.1007/s00247-002-0761-0>.
- [9] T.A. Burrow, et al., Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy, *J. Pediatr.* 150 (2007) 202–206, <https://doi.org/10.1016/j.jpeds.2006.10.062>.
- [10] B. Yağci, et al., Giant lymphadenopathy infiltrated by gaucher cells mimicking lymphoma, *Pediatr. Blood Cancer* 52 (2009) 870–871, <https://doi.org/10.1002/pbc.21948>.
- [11] D.J. Fowler, et al., Ultrastructural features of gaucher disease treated with enzyme replacement therapy presenting as mesenteric mass lesions, *Fetal Pediatr. Pathol.* 25 (2006) 241–248.
- [12] B.H. Lee, et al., Progressive mesenteric lymphadenopathy with protein-losing enteropathy; a devastating complication in Gaucher disease, *Mol. Genet. Metab.* 105 (2012) 522–524, <https://doi.org/10.1016/j.ymgme.2011.12.010>.
- [13] M. Biegstraaten, et al., Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease, *Blood Cell Mol. Dis.* (2016), <https://doi.org/10.1016/j.bcmd.2016.10.008>.
- [14] S.P. James, F.W. Stromeyer, C. Chang, J.A. Barranger, Liver abnormalities in patients with Gaucher's disease, *Gastroenterology* 80 (1981) 126–133.
- [15] S.C. Hill, J.W. Reinig, J.A. Barranger, J. Fink, T.H. Shawker, Gaucher disease: sonographic appearance of the spleen, *Radiology* 160 (1986) 631–634, <https://doi.org/10.1148/radiology.160.3.3526400>.
- [16] O. Neudorfer, I. Hadas-Halpern, D. Elstein, A. Abrahamov, A. Zimran, Abdominal ultrasound findings mimicking hematological malignancies in a study of 218

- Gaucher patients, *Am. J. Hematol.* 55 (1997) 28–34.
- [17] P. Stein, A. Malhotra, A. Haims, G.M. Pastores, P.K. Mistry, Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy, *J. Inher. Metab. Dis.* 33 (2010) 769–774, <https://doi.org/10.1007/s10545-010-9175-6>.
- [18] M.R. Terk, J. Esplin, K. Lee, G. Magre, P.M. Colletti, MR imaging of patients with type 1 Gaucher's disease: relationship between bone and visceral changes, *AJR Am. J. Roentgenol.* 165 (1995) 599–604, <https://doi.org/10.2214/ajr.165.3.7645477>.
- [19] S.C. Hill, et al., Gaucher disease: abdominal MR imaging findings in 46 patients, *Radiology* 184 (1992) 561–566, <https://doi.org/10.1148/radiology.184.2.1620865>.
- [20] P.K. Mistry, et al., Gaucher disease: Progress and ongoing challenges, *Mol. Genet. Metab.* 120 (2017) 8–21, <https://doi.org/10.1016/j.ymgme.2016.11.006>.
- [21] G. Monestime, et al., Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells, *Mol. Genet. Metab.* 118 (2016) 55–59, <https://doi.org/10.1016/j.ymgme.2016.02.008>.
- [22] L.A. Boven, et al., Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages, *Am. J. Clin. Pathol.* 122 (2004) 359–369, <https://doi.org/10.1309/bg5v-a8jr-dqh1-m7hn>.
- [23] M. Regenboog, et al., Imaging characteristics of focal splenic and hepatic lesions in type 1 Gaucher disease, *Blood Cells Mol. Dis.* 60 (2016) 49–57, <https://doi.org/10.1016/j.bcmd.2016.06.009>.
- [24] M. Abdelwahab, H.M. SeifEldien, Mesenteric and mediastinal lymphadenopathy in Egyptian children with Gaucher disease types 1 and 3 treated with enzyme replacement therapy, *J. Pediatr. Hematol. Oncol.* 37 (2015) e316–e322, <https://doi.org/10.1097/mpb.0000000000000297>.